About Nectar Life Sciences Limited
Data last updated: 18 December 2025
Nectar Life Sciences Limited is a public limited company based in Derabassi, Punjab, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 27 June 1995, the company has been in operation for over 31 years.
Registered with ROC Chandigarh under CIN L24232PB1995PLC016664. Listed on BSE: 532649 and NSE: NECLIFE.
Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹22.43 Cr. Formerly known as Surya Medicare Limited. It is led by directors including Indu Pal Kaur and Rupinder Tewari.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507.
The net worth stands at ₹582.3 Cr (down 39.1% YoY). Total assets are valued at ₹621.61 Cr (down 69.64% YoY).
The company has a workforce of approximately 1,814 employees as per the latest available data.
The company is associated with 1 brand - Nectar Lifesciences. As per MCA filings, the company has open charges of ₹60.47 Lakh and satisfied charges of ₹6,249.44 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website neclife.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered AddressShop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507
-
IndustryPharma, Drug Formulation & Development, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Nectar Life Sciences Limited
Nectar Life Sciences Limited has one previous CIN (Corporate Identification Number): U24232PB1995PLC016664. The current CIN is L24232PB1995PLC016664, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232PB1995PLC016664 | Current |
| U24232PB1995PLC016664 | Previous |
Associated Brands with Nectar Life Sciences Limited
Nectar Life Sciences Limited operates one associated brand: Nectar Lifesciences. These brands represent Nectar Life Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Cephalosporin APIs and generic formulations are manufactured. | neclife.com |
Business Activity of Nectar Life Sciences Limited
Nectar Life Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Nectar Life Sciences Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Nectar Life Sciences Limited
Nectar Life Sciences Limited is audited by Deepak Jindal & Co. (ICAI peer reviewed, certificate valid till 2027-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deepak Jindal & Co. (ICAI peer reviewed, certificate valid till 2027-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Nectar Life Sciences Limited
Nectar Life Sciences Limited is currently managed by 6 directors, with 26 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Indu Pal Kaur
Also directs:
Casanova R&D Private Limited
|
Director | 02 Aug 2022 | 4 Years 0 Months | Current |
|
Rupinder Tewari
Also directs:
Nureca Limited
|
Director | 11 Feb 2019 | 7 Years 6 Months | Current |
|
Kuldip Kumar Bhasin
Also directs:
Nureca Limited
|
Director | 21 Sep 2021 | 4 Years 10 Months | Current |
| Sushil Kapoor | Whole-Time Director | 04 Dec 2025 | 0 Years 8 Months | Current |
|
Sanjiv Goyal
Also directs:
Nectar Organics Private Limited
|
Managing Director | 27 Jun 1995 | 31 Years 1 Months | Current |
| Surulichamy Senthilkumar | Director | 10 Nov 2025 | 0 Years 9 Months | Current |
Financials of Nectar Life Sciences Limited FY 2026 filings available
Nectar Life Sciences Limited reported revenue of ₹- (down 100% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹0 | ₹1,673.07 Cr | ₹1,685.63 Cr | ₹1,524.61 Cr | ₹1,668.86 Cr | ₹1,544.37 Cr | ₹2,366.73 Cr |
| Other Income | ₹9.29 Cr | ₹1.89 Cr | ₹13.03 Cr | ₹42.24 Cr | ₹11.29 Cr | ₹2.72 Cr | ₹4.01 Cr |
| Total Income | ₹9.29 Cr | ₹1,674.97 Cr | ₹1,698.66 Cr | ₹1,566.85 Cr | ₹1,680.15 Cr | ₹1,547.09 Cr | ₹2,370.74 Cr |
| Cost of Materials Consumed | ₹0 | ₹1,250.72 Cr | ₹1,242.45 Cr | ₹1,200.84 Cr | ₹1,206.88 Cr | ₹1,028.4 Cr | ₹1,834.03 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹44.02 Lakh | ₹24.42 Cr | ₹28.8 Cr |
| Changes in Inventories | ₹0 | ₹117.29 Cr | -₹40.21 Cr | -₹41.55 Cr | ₹15.81 Cr | ₹104.29 Cr | -₹4.22 Cr |
| Employee Benefit Expense | ₹1.91 Cr | ₹96.47 Cr | ₹84.67 Cr | ₹77.78 Cr | ₹74.55 Cr | ₹73.37 Cr | ₹81 Cr |
| Finance Costs | ₹36.13 Cr | ₹74.58 Cr | ₹87.14 Cr | ₹79.49 Cr | ₹78.81 Cr | ₹112.03 Cr | ₹125.83 Cr |
| Depreciation & Amortisation | ₹34.26 Lakh | ₹62.39 Cr | ₹60.72 Cr | ₹59.12 Cr | ₹56.97 Cr | ₹60.25 Cr | ₹60.77 Cr |
| Other Expenses | ₹58.79 Cr | ₹235.05 Cr | ₹245.62 Cr | ₹233.6 Cr | ₹212.61 Cr | ₹203.77 Cr | ₹207.07 Cr |
| Total Expenses | ₹97.17 Cr | ₹1,836.5 Cr | ₹1,680.39 Cr | ₹1,609.27 Cr | ₹1,646.07 Cr | ₹1,606.54 Cr | ₹2,333.27 Cr |
| Profit Before Exceptional Items & Tax | -₹87.88 Cr | -₹161.53 Cr | ₹18.27 Cr | -₹42.42 Cr | ₹34.08 Cr | -₹59.45 Cr | ₹37.47 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹25.31 Cr | ₹0 |
| Profit Before Tax | -₹87.88 Cr | -₹161.53 Cr | ₹18.27 Cr | -₹42.42 Cr | ₹34.08 Cr | -₹84.77 Cr | ₹37.47 Cr |
| Total Tax Expense | -₹30.53 Cr | -₹47.85 Cr | ₹13.27 Cr | -₹18.24 Cr | ₹9.03 Cr | -₹11.5 Cr | ₹5.68 Cr |
| Net Profit | -₹292.89 Cr | -₹113.68 Cr | ₹4.99 Cr | -₹24.18 Cr | ₹25.05 Cr | -₹73.26 Cr | ₹31.79 Cr |
| attributable to Owners | - | - | ₹0 | ₹0 | ₹0 | - | - |
| attributable to NCI | - | - | ₹0 | ₹0 | ₹0 | - | - |
| Other Comprehensive Income | ₹7.94 Lakh | ₹53.98 Lakh | -₹34.13 Lakh | ₹87.22 Lakh | ₹82.87 Lakh | ₹39.85 Lakh | ₹52.88 Lakh |
| Total Comprehensive Income | -₹292.81 Cr | -₹113.14 Cr | ₹4.65 Cr | -₹23.31 Cr | ₹25.88 Cr | -₹72.87 Cr | ₹32.32 Cr |
| EBITDA (computed) | -₹51.41 Cr | -₹24.57 Cr | ₹166.13 Cr | ₹96.19 Cr | ₹169.86 Cr | ₹112.84 Cr | ₹224.06 Cr |
| Basic EPS | ₹-2.62 | ₹-5.07 | ₹0.22 | ₹-1.08 | ₹1.12 | ₹-3.27 | ₹1.42 |
| Diluted EPS | ₹-2.62 | ₹-5.07 | ₹0.22 | ₹-1.08 | ₹1.12 | ₹-3.27 | ₹1.42 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹621.61 Cr | ₹2,047.22 Cr | ₹2,191.06 Cr | ₹2,189.21 Cr |
| Non-current Assets | ₹332.78 Cr | ₹809.64 Cr | ₹907.22 Cr | ₹958.03 Cr |
| Current Assets | ₹252.97 Cr | ₹1,237.59 Cr | ₹1,283.83 Cr | ₹1,231.18 Cr |
| Property, Plant & Equipment | ₹103.4 Cr | ₹576.6 Cr | ₹590.31 Cr | ₹612.65 Cr |
| Inventories | ₹29.82 Lakh | ₹690.16 Cr | ₹709.15 Cr | ₹672.6 Cr |
| Trade Receivables | ₹0 | ₹345.48 Cr | ₹379.19 Cr | ₹279.61 Cr |
| Cash & Equivalents | ₹0 | ₹19.22 Cr | ₹19.81 Cr | ₹17.58 Cr |
| Equity (Net Worth) | ₹582.3 Cr | ₹956.11 Cr | ₹1,069.25 Cr | ₹1,064.59 Cr |
| Equity Share Capital | ₹19.43 Cr | ₹22.43 Cr | ₹22.43 Cr | ₹22.43 Cr |
| Borrowings (Non-current) | ₹0 | ₹60.13 Cr | ₹140.31 Cr | ₹226.47 Cr |
| Borrowings (Current) | ₹0 | ₹521.9 Cr | ₹495.23 Cr | ₹527.36 Cr |
| Total Debt (computed) | ₹0 | ₹582.02 Cr | ₹635.54 Cr | ₹753.83 Cr |
| Current Liabilities | ₹26.05 Cr | ₹1,021.54 Cr | ₹972.82 Cr | ₹890.93 Cr |
| Total Liabilities | ₹39.31 Cr | ₹1,091.12 Cr | ₹1,121.81 Cr | ₹1,124.62 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹348.72 Cr | ₹169.44 Cr | ₹224.69 Cr | ₹133.65 Cr | ₹95.01 Cr |
| Investing Cash Flow | ₹1,208.15 Cr | -₹41.93 Cr | -₹17.03 Cr | ₹51.7 Cr | ₹16.64 Cr |
| Financing Cash Flow | -₹766.51 Cr | -₹128.09 Cr | -₹205.43 Cr | -₹185.58 Cr | -₹119.38 Cr |
| Capital Expenditure | ₹12.27 Cr | ₹43.79 Cr | ₹29.42 Cr | ₹30.06 Cr | ₹24.97 Cr |
| Free Cash Flow (computed) | -₹361 Cr | ₹125.64 Cr | ₹195.27 Cr | ₹103.59 Cr | ₹70.04 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹92.91 Cr | -₹58.44 Lakh | ₹2.23 Cr | -₹22.79 Lakh | -₹7.73 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹0 | ₹0 | ₹5 Cr | ₹280.67 Cr | ₹430.69 Cr | ₹454.98 Cr | ₹428.1 Cr | ₹359.3 Cr | ₹441.37 Cr | ₹452.17 Cr | ₹397.96 Cr | ₹394.12 Cr |
| Other Income | ₹7.58 Cr | ₹66.08 Lakh | ₹74.07 Lakh | ₹34.99 Lakh | ₹7.77 Lakh | ₹57.3 Lakh | ₹68.94 Lakh | ₹55.08 Lakh | ₹1.47 Cr | ₹48.02 Lakh | ₹10.61 Cr | ₹47.31 Lakh |
| Total Income | ₹7.58 Cr | ₹66.08 Lakh | ₹5.74 Cr | ₹281.02 Cr | ₹430.77 Cr | ₹455.56 Cr | ₹428.79 Cr | ₹359.85 Cr | ₹442.84 Cr | ₹452.65 Cr | ₹408.57 Cr | ₹394.6 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹3.41 Cr | ₹236.07 Cr | ₹405.7 Cr | ₹294.15 Cr | ₹253.89 Cr | ₹296.98 Cr | ₹360.32 Cr | ₹342.32 Cr | ₹256.16 Cr | ₹283.65 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | -₹5.59 Lakh | ₹27.47 Cr | ₹96.88 Cr | ₹37.89 Cr | ₹42.16 Cr | -₹59.64 Cr | -₹52.39 Cr | -₹14.96 Cr | ₹31.63 Cr | -₹4.49 Cr |
| Employee Benefit Expense | ₹1.26 Cr | ₹60.95 Lakh | ₹75.17 Lakh | ₹24.26 Cr | ₹23.81 Cr | ₹24.5 Cr | ₹24.18 Cr | ₹23.99 Cr | ₹23.94 Cr | ₹21.62 Cr | ₹20.31 Cr | ₹18.8 Cr |
| Finance Costs | ₹5.9 Cr | ₹30.22 Cr | ₹0 | ₹18.7 Cr | ₹17.67 Cr | ₹17.12 Cr | ₹19.81 Cr | ₹19.98 Cr | ₹24.16 Cr | ₹24.84 Cr | ₹20.52 Cr | ₹17.62 Cr |
| Depreciation & Amortisation | ₹8.28 Lakh | ₹6.19 Lakh | ₹20.41 Lakh | ₹16.52 Cr | ₹15.77 Cr | ₹15.61 Cr | ₹15.55 Cr | ₹15.46 Cr | ₹14.7 Cr | ₹15.37 Cr | ₹15.31 Cr | ₹15.33 Cr |
| Other Expenses | ₹57.26 Cr | ₹1.32 Cr | ₹1.93 Cr | ₹54.76 Cr | ₹58.61 Cr | ₹53.73 Cr | ₹64.54 Cr | ₹58.17 Cr | ₹61 Cr | ₹60.99 Cr | ₹63 Cr | ₹60.62 Cr |
| Total Expenses | ₹64.51 Cr | ₹32.21 Cr | ₹6.24 Cr | ₹377.78 Cr | ₹618.44 Cr | ₹443.01 Cr | ₹420.12 Cr | ₹354.93 Cr | ₹431.73 Cr | ₹450.19 Cr | ₹406.93 Cr | ₹391.54 Cr |
| Profit Before Exceptional Items & Tax | -₹56.93 Cr | -₹31.55 Cr | -₹50.62 Lakh | -₹96.75 Cr | -₹187.67 Cr | ₹12.55 Cr | ₹8.67 Cr | ₹4.92 Cr | ₹11.11 Cr | ₹2.46 Cr | ₹1.64 Cr | ₹3.06 Cr |
| Exceptional Items | ₹0 | ₹88.15 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹56.93 Cr | ₹56.6 Cr | -₹50.62 Lakh | -₹96.75 Cr | -₹187.67 Cr | ₹12.55 Cr | ₹8.67 Cr | ₹4.92 Cr | ₹11.11 Cr | ₹2.46 Cr | ₹1.64 Cr | ₹3.06 Cr |
| Total Tax Expense | -₹19.72 Cr | -₹11.02 Cr | -₹17.69 Lakh | -₹33.52 Cr | -₹57.58 Cr | ₹4.71 Cr | ₹3.07 Cr | ₹1.95 Cr | ₹10.52 Cr | ₹88.96 Lakh | ₹62.62 Lakh | ₹1.24 Cr |
| Net Profit | -₹67.92 Cr | ₹14.27 Cr | -₹176.01 Cr | -₹63.23 Cr | -₹130.09 Cr | ₹7.84 Cr | ₹5.6 Cr | ₹2.97 Cr | ₹59.2 Lakh | ₹1.57 Cr | ₹1.02 Cr | ₹1.82 Cr |
| attributable to Owners | - | - | - | - | - | ₹0 | - | ₹0 | ₹0 | - | - | ₹0 |
| attributable to NCI | - | - | - | - | - | ₹0 | - | ₹0 | ₹0 | - | - | ₹0 |
| Other Comprehensive Income | ₹7.93 Lakh | ₹0 | ₹0 | ₹1,000 | ₹53.98 Lakh | ₹0 | ₹0 | ₹0 | -₹34.13 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹67.84 Cr | ₹14.27 Cr | -₹176.01 Cr | -₹63.23 Cr | -₹129.55 Cr | ₹7.84 Cr | ₹5.6 Cr | ₹2.97 Cr | ₹25.07 Lakh | ₹1.57 Cr | ₹1.02 Cr | ₹1.82 Cr |
| EBITDA (computed) | -₹50.95 Cr | -₹1.26 Cr | -₹30.21 Lakh | -₹61.54 Cr | -₹154.23 Cr | ₹45.28 Cr | ₹44.02 Cr | ₹40.35 Cr | ₹49.97 Cr | ₹42.67 Cr | ₹37.47 Cr | ₹36.01 Cr |
| Basic EPS | ₹-1.85 | ₹3.02 | ₹-0.01 | ₹-2.82 | ₹-5.80 | ₹0.35 | ₹0.25 | ₹0.13 | ₹0.03 | ₹0.07 | ₹0.05 | ₹0.08 |
| Diluted EPS | ₹-1.85 | ₹3.02 | ₹-0.01 | ₹-2.82 | ₹-5.80 | ₹0.35 | ₹0.25 | ₹0.13 | ₹0.03 | ₹0.07 | ₹0.05 | ₹0.08 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹0 | ₹1,673.07 Cr | ₹1,685.63 Cr | ₹1,524.61 Cr | ₹1,542.9 Cr | ₹2,363.16 Cr |
| Other Income | ₹9.29 Cr | ₹1.89 Cr | ₹13.03 Cr | ₹42.24 Cr | ₹2.72 Cr | ₹4.01 Cr |
| Total Income | ₹9.29 Cr | ₹1,674.97 Cr | ₹1,698.66 Cr | ₹1,566.85 Cr | ₹1,545.62 Cr | ₹2,367.16 Cr |
| Cost of Materials Consumed | ₹0 | ₹1,250.72 Cr | ₹1,242.45 Cr | ₹1,200.84 Cr | ₹1,028.4 Cr | ₹1,834.03 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹24.42 Cr | ₹28.8 Cr |
| Changes in Inventories | ₹0 | ₹117.29 Cr | -₹40.21 Cr | -₹41.64 Cr | ₹102.8 Cr | -₹5.25 Cr |
| Employee Benefit Expense | ₹1.9 Cr | ₹96.47 Cr | ₹84.67 Cr | ₹77.78 Cr | ₹73.37 Cr | ₹81 Cr |
| Finance Costs | ₹36.13 Cr | ₹74.58 Cr | ₹87.14 Cr | ₹79.48 Cr | ₹112.03 Cr | ₹125.82 Cr |
| Depreciation & Amortisation | ₹34.26 Lakh | ₹62.39 Cr | ₹60.72 Cr | ₹59.12 Cr | ₹60.25 Cr | ₹60.77 Cr |
| Other Expenses | ₹58.79 Cr | ₹235.05 Cr | ₹245.61 Cr | ₹231.97 Cr | ₹203.68 Cr | ₹206.25 Cr |
| Total Expenses | ₹97.16 Cr | ₹1,836.5 Cr | ₹1,680.39 Cr | ₹1,607.54 Cr | ₹1,604.95 Cr | ₹2,331.42 Cr |
| Profit Before Exceptional Items & Tax | -₹87.87 Cr | -₹161.53 Cr | ₹18.28 Cr | -₹40.69 Cr | -₹59.34 Cr | ₹35.74 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | -₹25.31 Cr | ₹0 |
| Profit Before Tax | -₹87.87 Cr | -₹161.53 Cr | ₹18.28 Cr | -₹40.69 Cr | -₹84.65 Cr | ₹35.74 Cr |
| Total Tax Expense | -₹30.53 Cr | -₹47.85 Cr | ₹13.27 Cr | -₹18.24 Cr | -₹11.5 Cr | ₹5.68 Cr |
| Net Profit | -₹292.88 Cr | -₹113.68 Cr | ₹5 Cr | -₹22.46 Cr | -₹73.15 Cr | ₹30.06 Cr |
| Other Comprehensive Income | ₹7.92 Lakh | ₹53.98 Lakh | -₹34.19 Lakh | ₹18.78 Lakh | ₹39.36 Lakh | ₹1.26 Cr |
| Total Comprehensive Income | -₹292.81 Cr | -₹113.14 Cr | ₹4.66 Cr | -₹22.27 Cr | -₹72.75 Cr | ₹31.32 Cr |
| EBITDA (computed) | -₹51.4 Cr | -₹24.57 Cr | ₹166.14 Cr | ₹97.9 Cr | ₹112.95 Cr | ₹222.33 Cr |
| Basic EPS | ₹-2.62 | ₹-5.07 | ₹0.22 | ₹-1.00 | ₹-3.26 | ₹1.34 |
| Diluted EPS | ₹-2.62 | ₹-5.07 | ₹0.22 | ₹-1.00 | ₹-3.26 | ₹1.34 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹612.34 Cr | ₹2,047.23 Cr | ₹2,191.06 Cr | ₹2,189.21 Cr |
| Non-current Assets | ₹326.92 Cr | ₹809.65 Cr | ₹907.23 Cr | ₹958.04 Cr |
| Current Assets | ₹249.57 Cr | ₹1,237.59 Cr | ₹1,283.83 Cr | ₹1,231.18 Cr |
| Property, Plant & Equipment | ₹3.45 Cr | ₹576.6 Cr | ₹590.31 Cr | ₹612.65 Cr |
| Inventories | ₹29.82 Lakh | ₹690.16 Cr | ₹709.15 Cr | ₹672.6 Cr |
| Trade Receivables | ₹0 | ₹345.48 Cr | ₹379.19 Cr | ₹279.61 Cr |
| Cash & Equivalents | ₹0 | ₹19.22 Cr | ₹19.8 Cr | ₹17.57 Cr |
| Equity (Net Worth) | ₹582.31 Cr | ₹956.11 Cr | ₹1,069.25 Cr | ₹1,064.59 Cr |
| Equity Share Capital | ₹19.43 Cr | ₹22.43 Cr | ₹22.43 Cr | ₹22.43 Cr |
| Borrowings (Non-current) | ₹0 | ₹60.13 Cr | ₹140.31 Cr | ₹226.47 Cr |
| Borrowings (Current) | ₹0 | ₹521.9 Cr | ₹495.23 Cr | ₹527.36 Cr |
| Total Debt (computed) | ₹0 | ₹582.02 Cr | ₹635.54 Cr | ₹753.83 Cr |
| Current Liabilities | ₹25.97 Cr | ₹1,021.54 Cr | ₹972.82 Cr | ₹890.93 Cr |
| Total Liabilities | ₹30.04 Cr | ₹1,091.12 Cr | ₹1,121.81 Cr | ₹1,124.62 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹417.35 Cr | ₹169.44 Cr | ₹224.69 Cr | ₹133.37 Cr |
| Investing Cash Flow | ₹1,205.41 Cr | -₹41.93 Cr | -₹17.03 Cr | ₹52.03 Cr |
| Financing Cash Flow | -₹699.15 Cr | -₹128.09 Cr | -₹205.43 Cr | -₹185.57 Cr |
| Capital Expenditure | ₹11.53 Cr | ₹43.79 Cr | ₹29.42 Cr | ₹30.06 Cr |
| Free Cash Flow (computed) | -₹428.88 Cr | ₹125.64 Cr | ₹195.28 Cr | ₹103.31 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹88.91 Cr | -₹58.45 Lakh | ₹2.23 Cr | -₹16.66 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹0 | ₹0 | ₹5 Cr | ₹280.67 Cr | ₹430.69 Cr | ₹454.98 Cr | ₹428.1 Cr | ₹359.3 Cr | ₹441.37 Cr | ₹452.17 Cr | ₹397.96 Cr | ₹394.12 Cr |
| Other Income | ₹7.58 Cr | ₹66.08 Lakh | ₹74.07 Lakh | ₹34.99 Lakh | ₹7.77 Lakh | ₹57.3 Lakh | ₹68.94 Lakh | ₹55.08 Lakh | ₹1.47 Cr | ₹48.02 Lakh | ₹10.61 Cr | ₹47.31 Lakh |
| Total Income | ₹7.58 Cr | ₹66.08 Lakh | ₹5.74 Cr | ₹281.02 Cr | ₹430.77 Cr | ₹455.56 Cr | ₹428.79 Cr | ₹359.85 Cr | ₹442.84 Cr | ₹452.65 Cr | ₹408.57 Cr | ₹394.6 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹3.41 Cr | ₹236.07 Cr | ₹405.7 Cr | ₹294.15 Cr | ₹253.89 Cr | ₹296.98 Cr | ₹360.32 Cr | ₹342.32 Cr | ₹256.16 Cr | ₹283.65 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | -₹5.59 Lakh | ₹27.47 Cr | ₹96.88 Cr | ₹37.89 Cr | ₹42.16 Cr | -₹59.64 Cr | -₹52.39 Cr | -₹14.96 Cr | ₹31.63 Cr | -₹4.49 Cr |
| Employee Benefit Expense | ₹1.25 Cr | ₹60.95 Lakh | ₹75.17 Lakh | ₹24.26 Cr | ₹23.81 Cr | ₹24.5 Cr | ₹24.18 Cr | ₹23.99 Cr | ₹23.94 Cr | ₹21.62 Cr | ₹20.31 Cr | ₹18.8 Cr |
| Finance Costs | ₹5.9 Cr | ₹30.22 Cr | ₹0 | ₹18.7 Cr | ₹17.67 Cr | ₹17.12 Cr | ₹19.81 Cr | ₹19.98 Cr | ₹24.16 Cr | ₹24.84 Cr | ₹20.52 Cr | ₹17.62 Cr |
| Depreciation & Amortisation | ₹8.28 Lakh | ₹6.19 Lakh | ₹20.41 Lakh | ₹16.52 Cr | ₹15.77 Cr | ₹15.61 Cr | ₹15.55 Cr | ₹15.46 Cr | ₹14.7 Cr | ₹15.37 Cr | ₹15.31 Cr | ₹15.33 Cr |
| Other Expenses | ₹57.26 Cr | ₹1.32 Cr | ₹1.93 Cr | ₹54.76 Cr | ₹58.61 Cr | ₹53.73 Cr | ₹64.54 Cr | ₹58.17 Cr | ₹61 Cr | ₹60.99 Cr | ₹63 Cr | ₹60.62 Cr |
| Total Expenses | ₹64.5 Cr | ₹32.21 Cr | ₹6.24 Cr | ₹377.78 Cr | ₹618.44 Cr | ₹443.01 Cr | ₹420.12 Cr | ₹354.93 Cr | ₹431.72 Cr | ₹450.19 Cr | ₹406.93 Cr | ₹391.54 Cr |
| Profit Before Exceptional Items & Tax | -₹56.92 Cr | -₹31.55 Cr | -₹50.62 Lakh | -₹96.75 Cr | -₹187.67 Cr | ₹12.55 Cr | ₹8.67 Cr | ₹4.92 Cr | ₹11.12 Cr | ₹2.46 Cr | ₹1.64 Cr | ₹3.06 Cr |
| Exceptional Items | ₹0 | ₹88.15 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹56.92 Cr | ₹56.6 Cr | -₹50.62 Lakh | -₹96.75 Cr | -₹187.67 Cr | ₹12.55 Cr | ₹8.67 Cr | ₹4.92 Cr | ₹11.12 Cr | ₹2.46 Cr | ₹1.64 Cr | ₹3.06 Cr |
| Total Tax Expense | -₹19.71 Cr | -₹11.02 Cr | -₹17.69 Lakh | -₹33.52 Cr | -₹57.58 Cr | ₹4.71 Cr | ₹3.07 Cr | ₹1.95 Cr | ₹10.52 Cr | ₹88.96 Lakh | ₹62.62 Lakh | ₹1.24 Cr |
| Net Profit | -₹67.92 Cr | ₹14.27 Cr | -₹176.01 Cr | -₹63.23 Cr | -₹130.09 Cr | ₹7.84 Cr | ₹5.6 Cr | ₹2.97 Cr | ₹59.91 Lakh | ₹1.57 Cr | ₹1.02 Cr | ₹1.82 Cr |
| Other Comprehensive Income | ₹7.92 Lakh | ₹0 | ₹0 | ₹0 | ₹53.98 Lakh | ₹0 | ₹0 | ₹0 | -₹34.19 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹67.84 Cr | ₹14.27 Cr | -₹176.01 Cr | -₹63.23 Cr | -₹129.55 Cr | ₹7.84 Cr | ₹5.6 Cr | ₹2.97 Cr | ₹25.72 Lakh | ₹1.57 Cr | ₹1.02 Cr | ₹1.82 Cr |
| EBITDA (computed) | -₹50.94 Cr | -₹1.26 Cr | -₹30.21 Lakh | -₹61.54 Cr | -₹154.23 Cr | ₹45.28 Cr | ₹44.02 Cr | ₹40.35 Cr | ₹49.98 Cr | ₹42.67 Cr | ₹37.47 Cr | ₹36.01 Cr |
| Basic EPS | ₹-1.85 | ₹3.02 | ₹-0.01 | ₹-2.82 | ₹-5.80 | ₹0.35 | ₹0.25 | ₹0.13 | ₹0.03 | ₹0.07 | ₹0.05 | ₹0.08 |
| Diluted EPS | ₹-1.85 | ₹3.02 | ₹-0.01 | ₹-2.82 | ₹-5.80 | ₹0.35 | ₹0.25 | ₹0.13 | ₹0.03 | ₹0.07 | ₹0.05 | ₹0.08 |
Shareholding Pattern of Nectar Life Sciences Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.84%, foreign institutional investors hold 0.60%, domestic institutional investors hold 4.01%, retail and other public shareholders hold 43.52% of Nectar Life Sciences Limited. The company had 74,834 shareholders on record.
| Mar 2026 | Jan 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 51.84% | 51.84% | 44.91% | 44.91% | 44.53% | 44.53% |
| Public | 48.16% | 48.16% | 55.09% | 55.09% | 55.47% | 55.47% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.84% | 44.53% | 55.80% | 55.80% | 55.80% | 55.80% | 55.80% | 55.80% | 55.80% | 55.80% | 55.80% |
| Public | 48.16% | 55.47% | 44.20% | 44.20% | 44.20% | 44.20% | 44.20% | 44.20% | 44.20% | 44.20% | 44.20% |
| Promoter change (YoY, %pts) | +7.31 | -11.27 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | +0.00 | - |
Board & Governance of Nectar Life Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Nectar Life Sciences Limited has 6 directors - 3 independent and 2 executive. The board is chaired by SANJIV GOYAL.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| SANJIV GOYAL | Executive Director · MD · Chairperson | 1995-06-27 | 1 |
| RUPINDER TEWARI | Non-Executive - Independent Director | 2019-02-11 | 2 |
| KULDIP KUMAR BHASIN | Non-Executive - Independent Director | 2021-09-21 | 2 |
| INDU PAL KAUR | Non-Executive - Independent Director | 2022-08-02 | 1 |
| SURULICHAMY SENTHILKUMAR | Non-Executive - Non Independent Director | 2025-06-01 | 1 |
| SUSHIL KAPOOR | Executive Director | 2025-12-04 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | RUPINDER TEWARI (Chairperson), KULDIP KUMAR BHASIN, INDU PAL KAUR, SANJIV GOYAL |
| Nomination and remuneration committee | RUPINDER TEWARI (Chairperson), KULDIP KUMAR BHASIN, INDU PAL KAUR |
| Stakeholders Relationship Committee | KULDIP KUMAR BHASIN (Chairperson), SANJIV GOYAL, SURULICHAMY SENTHILKUMAR |
| Risk Management Committee | SANJIV GOYAL (Chairperson), RUPINDER TEWARI, SUSHIL KAPOOR |
| Corporate Social Responsibility Committee | SANJIV GOYAL (Chairperson), KULDIP KUMAR BHASIN, SURULICHAMY SENTHILKUMAR |
| MANAGEMENT COMMITTEE | SANJIV GOYAL (Chairperson), SURULICHAMY SENTHILKUMAR, SUSHIL KAPOOR |
Charges & Borrowings of Nectar Life Sciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Dec 2023 | Hdfc Bank Limited | ₹60.47 Lakh | Satisfied |
| 28 Jun 2022 | Hdfc Bank Limited | ₹20 Lakh | Satisfied |
| 01 Dec 2021 | Hdfc Bank Limited | ₹20 Lakh | Satisfied |
| 14 Jul 2021 | Hdfc Bank Limited | ₹6 Lakh | Satisfied |
| 21 Jun 2021 | Sbicap Trustee Company Limited | ₹1,338.35 Cr | Satisfied |
Total charge records: 111 View all charges
Employees and EPFO Compliance at Nectar Life Sciences Limited
Nectar Life Sciences Limited has a workforce of 1,814 employees as of Nov 28, 2025.
Employee and EPFO history for Nectar Life Sciences Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Nectar Life Sciences Limited
GST registrations and filing compliance for Nectar Life Sciences Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Nectar Life Sciences Limited
Credit ratings, litigation, and regulatory alerts for Nectar Life Sciences Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Nectar Life Sciences Limited
MSME payment history for Nectar Life Sciences Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Nectar Life Sciences Limited
Corporate group structure for Nectar Life Sciences Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Nectar Life Sciences Limited
MCA filings and documents for Nectar Life Sciences Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Nectar Life Sciences Limited
Recent News on Nectar Life Sciences Limited
Frequently Asked Questions about Nectar Life Sciences Limited
Nectar Life Sciences Limited is an active public limited company in the pharma sector based in Derabassi, Punjab, India. It was incorporated on 27 June 1995 (31+ years old) and is registered under CIN L24232PB1995PLC016664. Listed on BSE: 532649 and NSE: NECLIFE. The company has 1,814 employees.
The current directors of Nectar Life Sciences Limited are:
- Indu Pal Kaur - Director
- Rupinder Tewari - Director
- Kuldip Kumar Bhasin - Director
- Sushil Kapoor - Whole-Time Director
- Sanjiv Goyal - Managing Director
- Surulichamy Senthilkumar - Director
The primary industry of Nectar Life Sciences Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Nectar Life Sciences Limited is listed on both BSE (code: 532649) and NSE (symbol: NECLIFE).
Nectar Life Sciences Limited can be reached at the registered office: Shop No. 5 Sl Enclave Behind Sohi Hp Gas Agency, Barwala Road Derabassi Distt. S.A.S Nagar, Punjab, India – 140507, or through the website neclife.com.
The authorised capital is ₹35 Cr, and the paid-up capital is ₹22.43 Cr.